Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit | The Motley Fool
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Source: The Motley Fool
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.